These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32606002)
1. Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. Sholl LM; Oxnard GR; Paweletz CP Cancer Res; 2020 Aug; 80(16):3197-3199. PubMed ID: 32606002 [TBL] [Abstract][Full Text] [Related]
2. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536 [TBL] [Abstract][Full Text] [Related]
3. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients]. Hekmat K; Bruns C Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676 [No Abstract] [Full Text] [Related]
4. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770 [TBL] [Abstract][Full Text] [Related]
7. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Malapelle U; Rossi G; Pisapia P; Barberis M; Buttitta F; Castiglione F; Cecere FL; Grimaldi AM; Iaccarino A; Marchetti A; Massi D; Medicina D; Mele F; Minari R; Orlando E; Pagni F; Palmieri G; Righi L; Russo A; Tommasi S; Vermi W; Troncone G Crit Rev Oncol Hematol; 2020 Dec; 156():103118. PubMed ID: 33038627 [TBL] [Abstract][Full Text] [Related]
8. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
10. Tumor-educated platelet as liquid biopsy in lung cancer patients. Liu L; Lin F; Ma X; Chen Z; Yu J Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. Park CK; Kim JE; Kim MS; Kho BG; Park HY; Kim TO; Shin HJ; Cho HJ; Choi YD; Oh IJ; Kim YC J Cancer Res Clin Oncol; 2019 Aug; 145(8):2071-2082. PubMed ID: 31154543 [TBL] [Abstract][Full Text] [Related]
12. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Meador CB; Micheel CM; Levy MA; Lovly CM; Horn L; Warner JL; Johnson DB; Zhao Z; Anderson IA; Sosman JA; Vnencak-Jones CL; Dahlman KB; Pao W Clin Cancer Res; 2014 May; 20(9):2264-75. PubMed ID: 24599935 [TBL] [Abstract][Full Text] [Related]
13. What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. Bernicker EH Arch Pathol Lab Med; 2019 Sep; 143(9):1089-1092. PubMed ID: 31100016 [No Abstract] [Full Text] [Related]
14. Somatic mutations and immune checkpoint biomarkers. Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374 [TBL] [Abstract][Full Text] [Related]
15. Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. Naso J; Lo YC; Sholl LM J Surg Oncol; 2023 Feb; 127(2):244-257. PubMed ID: 36630101 [TBL] [Abstract][Full Text] [Related]
16. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Potter AJ; Colebatch AJ; Rawson RV; Ferguson PM; Cooper WA; Gupta R; O'Toole S; Saw RPM; Ch'ng S; Menzies AM; Long GV; Scolyer RA Pathology; 2022 Aug; 54(5):526-532. PubMed ID: 35249747 [TBL] [Abstract][Full Text] [Related]
17. Predictive markers in lung cancer: a few hints for the practicing pathologist. Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911 [TBL] [Abstract][Full Text] [Related]
18. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770 [TBL] [Abstract][Full Text] [Related]
19. Biomarkers for personalized oncology: recent advances and future challenges. Kalia M Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140 [TBL] [Abstract][Full Text] [Related]
20. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients. Peng H; Lu L; Zhou Z; Liu J; Zhang D; Nan K; Zhao X; Li F; Tian L; Dong H; Yao Y Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31739500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]